pamidronate has been researched along with Bone Diseases in 54 studies
Bone Diseases: Diseases of BONES.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Patients with multiple myeloma who were starting antimyeloma treatment were randomly assigned in a 1:1 ratio to receive one of two doses of pamidronate (30 mg or 90 mg) given by intravenous infusion once a month for at least 3 years." | 9.14 | Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. ( Abildgaard, N; Ahlberg, L; Andersen, NF; Carlson, K; Dahl, IM; Fayers, P; Gimsing, P; Gluud, C; Gregersen, H; Hjorth, M; Hjorth-Hansen, H; Juliusson, G; Knudsen, LM; Linder, O; Mylin, A; Nesthus, I; Nielsen, JL; Turesson, I; Vangsted, A; Waage, A; Westin, J; Wisløff, F, 2010) |
| " To evaluate the therapeutic effects of Disodium Pamidronate (Bonin) on bone pain in multiple myeloma." | 9.10 | [Effects of pamidronate disodium (Bonin) combined with chemotherapy on bone pain in multiple myeloma]. ( Chen, SL; Leng, Y; Shi, HZ, 2002) |
| "The goal of the current study was to compare the long-term (25-month) safety and efficacy of zoledronic acid with pamidronate in patients with bone lesions secondary to advanced breast carcinoma or multiple myeloma." | 9.10 | Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. ( Apffelstaedt, J; Belch, A; Chen, BL; Coleman, RE; Gordon, D; Howell, A; Hussein, MA; Kaminski, M; Mackey, J; Reitsma, DJ; Rosen, LS; Seaman, JJ, 2003) |
| "To assess whether pamidronate can reduce the frequency of skeletal morbidity in women with lytic bone metastases from breast cancer treated with hormone therapy." | 9.09 | Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. ( Costello, S; Glück, S; Heffernan, M; Hortobagyi, GN; Kennedy, I; Knight, RD; Leff, R; Lipton, A; Mellars, K; Reitsma, DJ; Seaman, JJ; Simeone, J; Stewart, JF; Theriault, RL, 1999) |
| "It is unclear whether the new anti-catabolic agent denosumab represents a viable alternative to the widely used anti-catabolic agent pamidronate in the treatment of Multiple Myeloma (MM)-induced bone disease." | 7.78 | In silico investigations of the anti-catabolic effects of pamidronate and denosumab on multiple myeloma-induced bone disease. ( Lin, B; Wang, Y, 2012) |
| "Thalidomide is an effective maintenance therapy in patients with multiple myeloma." | 6.72 | Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. ( Attal, M; Avet-Loiseau, H; Benboubker, L; Berthou, C; Bourhis, JH; Caillot, D; Doyen, C; Dumontet, C; Facon, T; Garderet, L; Grobois, B; Harousseau, JL; Hulin, C; Leyvraz, S; Marit, G; Monconduit, M; Moreau, P; Pegourie, B; Renaud, M; Voillat, L; Yakoub Agha, I, 2006) |
| "Pamidronate treatment also did not have any influence on patient survival or on the frequency of hypercalcaemia." | 6.69 | Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group. ( Abildgaard, N; Brincker, H; Ford, J; Gimsing, P; Hedenus, M; Kandra, A; Turesson, I; Westin, J, 1998) |
| " Oral etidronate given daily showed no clinical benefit, whereas the use of oral clodronate daily did reduce the development of new osteolytic lesions but did not significantly affect bone pain or rates of pathologic fractures." | 6.18 | Bisphosphonates in multiple myeloma. ( Berenson, JR, 1997) |
| " Patients with multiple myeloma who were starting antimyeloma treatment were randomly assigned in a 1:1 ratio to receive one of two doses of pamidronate (30 mg or 90 mg) given by intravenous infusion once a month for at least 3 years." | 5.14 | Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. ( Abildgaard, N; Ahlberg, L; Andersen, NF; Carlson, K; Dahl, IM; Fayers, P; Gimsing, P; Gluud, C; Gregersen, H; Hjorth, M; Hjorth-Hansen, H; Juliusson, G; Knudsen, LM; Linder, O; Mylin, A; Nesthus, I; Nielsen, JL; Turesson, I; Vangsted, A; Waage, A; Westin, J; Wisløff, F, 2010) |
| "Patients with either progressive bone metastases or SREs while on clodronate or pamidronate may experience significant pain palliation with a switch to a more potent bisphosphonate." | 5.13 | A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy. ( Clemons, M; Cole, DE; Dranitsaris, G; Ooi, W, 2008) |
| " To evaluate the therapeutic effects of Disodium Pamidronate (Bonin) on bone pain in multiple myeloma." | 5.10 | [Effects of pamidronate disodium (Bonin) combined with chemotherapy on bone pain in multiple myeloma]. ( Chen, SL; Leng, Y; Shi, HZ, 2002) |
| "The goal of the current study was to compare the long-term (25-month) safety and efficacy of zoledronic acid with pamidronate in patients with bone lesions secondary to advanced breast carcinoma or multiple myeloma." | 5.10 | Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. ( Apffelstaedt, J; Belch, A; Chen, BL; Coleman, RE; Gordon, D; Howell, A; Hussein, MA; Kaminski, M; Mackey, J; Reitsma, DJ; Rosen, LS; Seaman, JJ, 2003) |
| "To assess whether pamidronate can reduce the frequency of skeletal morbidity in women with lytic bone metastases from breast cancer treated with hormone therapy." | 5.09 | Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. ( Costello, S; Glück, S; Heffernan, M; Hortobagyi, GN; Kennedy, I; Knight, RD; Leff, R; Lipton, A; Mellars, K; Reitsma, DJ; Seaman, JJ; Simeone, J; Stewart, JF; Theriault, RL, 1999) |
| "We studied the acute phase response, including specific cytokine production, [interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor alpha(TNF alpha)] following a single dose of Aredia (disodium pamidronate) in patients with increased bone turnover and, in vitro, the role played by specific cytokines in the acute-phase reaction which may follow the administration of aminobisphosphonates." | 5.08 | An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. ( Burckhardt, P; Green, JR; Ibarra de Palacios, P; Kandra, A; Leuenberger, P; Sauty, A; Sitzler, L; Thiébaud, D; Zieschang, J, 1997) |
| "Zoledronic acid and pamidronate are two potent anticatabolic nitrogen-containing bisphosphonates (BPs) used extensively in diseases with high bone turnover such as multiple myeloma (MM)." | 4.87 | The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future. ( Pozzi, S; Raje, N, 2011) |
| " In multiple myeloma, one study with oral clodronate has reported a decrease in bone events and two other studies, one with intravenous pamidronate and the other with oral clodronate have both reported a decrease in skeletal events and bone pain." | 4.80 | [Bisphosphonates and bone metastases]. ( Berthaud, P; Jadaud, E; Lortholary, A, 1999) |
| "No anabolic drugs are currently approved to treat multiple myeloma (MM)-induced bone disease and the anti-MM agent bortezomib exhibits the anabolic effects in the clinic." | 3.79 | In silico investigations of potential anabolic treatments in multiple myeloma-induced bone disease. ( Lin, B; Wang, Y, 2013) |
| "Our results show that the majority of patients with breast cancer, who develop bony metastases in Newfoundland and Labrador, are initially treated with the bisphosphonate, pamidronate." | 3.79 | Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre. ( Edwards, S; Laing, K; McCarthy, J; McCrate, F; Murphy, L; Powell, E; Seal, M, 2013) |
| "It is unclear whether the new anti-catabolic agent denosumab represents a viable alternative to the widely used anti-catabolic agent pamidronate in the treatment of Multiple Myeloma (MM)-induced bone disease." | 3.78 | In silico investigations of the anti-catabolic effects of pamidronate and denosumab on multiple myeloma-induced bone disease. ( Lin, B; Wang, Y, 2012) |
| " Intravenous pamidronate treatment given monthly for a year was well tolerated and produced dramatic clinical effects, with reduction in bone pain and improvements in mobility, despite incomplete suppression of bone resorption as assessed by biochemical, radiographic and histological criteria." | 3.71 | The osteodystrophy of mucolipidosis type III and the effects of intravenous pamidronate treatment. ( Baker, N; Cundy, T; David, G; Hofman, P; King, A; Noble, J; Robinson, C; Sillence, D, 2002) |
| " Bone densitometry is particularly effective for early detection of patients at risk for fracture and is of practical interest since patients with osteoporosis can now be treated with Pamidronate." | 3.71 | [Bone evaluation in ten adults with cutaneous mastocytosis]. ( Armingaud, P; Benhamou, CL; Estève, E; Kerdraon, R; Lespessailles, E; Petavy-Catala, C; Zerkak, D, 2002) |
| "For patients with prostate cancer, the choice between these 2 bisphosphonates must be balanced between the shorter infusion time of zoledronic acid versus its increased costs." | 2.75 | Risk of skeletal-related events in patients with advanced prostate cancer treated with pamidronate or zoledronic acid. ( Chan, J; Hui, RL; Schottinger, JE; Spence, MM, 2010) |
| "Thalidomide is an effective maintenance therapy in patients with multiple myeloma." | 2.72 | Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. ( Attal, M; Avet-Loiseau, H; Benboubker, L; Berthou, C; Bourhis, JH; Caillot, D; Doyen, C; Dumontet, C; Facon, T; Garderet, L; Grobois, B; Harousseau, JL; Hulin, C; Leyvraz, S; Marit, G; Monconduit, M; Moreau, P; Pegourie, B; Renaud, M; Voillat, L; Yakoub Agha, I, 2006) |
| "Pamidronate is a second-generation bisphosphonate that has been used to attenuate post-renal transplant bone loss, but its effect on the function of the renal allograft is unclear." | 2.71 | Pamidronate used to attenuate post-renal transplant bone loss is not associated with renal dysfunction. ( Coco, M; Glicklich, D; Lee, S, 2004) |
| "Pamidronate treatment also did not have any influence on patient survival or on the frequency of hypercalcaemia." | 2.69 | Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group. ( Abildgaard, N; Brincker, H; Ford, J; Gimsing, P; Hedenus, M; Kandra, A; Turesson, I; Westin, J, 1998) |
| "Pamidronate is a second-generation aminobisphosphonate that is a much more potent inhibitor of osteoclastic activity." | 2.40 | Bisphosphonates and breast carcinoma. ( Lipton, A, 1997) |
| "Conversely, in Paget's disease and prostate cancer-induced bone metastases, conditions characterized by focal increased bone turnover, alpha L CTX levels were more elevated than those of age-related CTX forms, resulting in increased ratios between native and age-modified CTX." | 1.32 | Investigation of bone disease using isomerized and racemized fragments of type I collagen. ( Body, JJ; Christgau, S; Christiansen, C; Cloos, PA; Delmas, P; Engsig, M; Fledelius, C; Garnero, P, 2003) |
| "To validate our hypothesis that a bisphosphonate (BP) having a nitrogen-containing heterocyclic ring on the side chain, and with no hydroxyl on the geminal carbon would possess increased activity, and better oral bioavailability due to enhanced solubility of its calcium complexes/salts and weaker Ca chelating properties." | 1.30 | Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio) ethylidene-1,1-bisphosphonic acid betaine (ISA-13-1)-a novel bisphosphonate. ( Alferiev, IS; Breuer, E; Cohen, H; Ezra, A; Golomb, G; Hägele, G; Hoffman, A; Mönkkönen, J; Ornoy, A; Patlas, N; Pinto, T; Sagi, H; Seibel, MJ; Solomon, V; Stepensky, D, 1999) |
| "Gaucher disease is the most prevalent lysosomal storage disorder." | 1.29 | Aminohydroxypropylidene-biphosphonate in the treatment of bone lesions in a case of Gaucher's disease type 3. ( Agosti, E; Bembi, B; Boehm, P; Nassimbeni, G; Vidoni, L; Zanatta, M, 1994) |
| "Hepatitis C has recently been recognized as a secondary cause of osteosclerosis; a further example, the first outside of North America, is described." | 1.29 | Acquired osteosclerosis associated with intravenous drug use and hepatitis C infection. ( Depczynski, B; Diamond, T, 1996) |
| "Two patients with Type 1 (adult) Gaucher's disease and major skeletal involvement with multiple fractures have been treated with the second generation bisphosphonate pamidronate for extensive periods." | 1.28 | Treatment of type 1 Gaucher's disease affecting bone with aminohydroxypropylidene bisphosphonate (pamidronate). ( Hesp, R; Hulme, P; Meunier, PJ; Ostlere, L; Reeve, J; Warner, T; Watts, RW, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.85) | 18.7374 |
| 1990's | 19 (35.19) | 18.2507 |
| 2000's | 14 (25.93) | 29.6817 |
| 2010's | 18 (33.33) | 24.3611 |
| 2020's | 2 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Barbosa, JS | 1 |
| Almeida Paz, FA | 1 |
| Braga, SS | 1 |
| Anthony, MD | 1 |
| Swilling, A | 1 |
| Jiwani, ZM | 1 |
| Heym, K | 1 |
| Margraf, LR | 1 |
| Fierke, S | 1 |
| Akers, LJ | 1 |
| Ray, A | 1 |
| Mhaskar, R | 2 |
| Kumar, A | 2 |
| Miladinovic, B | 2 |
| Djulbegovic, B | 2 |
| Leng, S | 1 |
| Chen, Y | 1 |
| Tsai, WY | 1 |
| Bhutani, D | 1 |
| Hillyer, GC | 1 |
| Lim, E | 1 |
| Accordino, MK | 1 |
| Wright, JD | 1 |
| Hershman, DL | 1 |
| Lentzsch, S | 2 |
| Neugut, AI | 1 |
| Wang, Y | 2 |
| Lin, B | 2 |
| Terpos, E | 3 |
| Morgan, G | 1 |
| Dimopoulos, MA | 2 |
| Drake, MT | 1 |
| Raje, N | 2 |
| Sezer, O | 1 |
| García-Sanz, R | 1 |
| Shimizu, K | 1 |
| Turesson, I | 3 |
| Reiman, T | 1 |
| Jurczyszyn, A | 1 |
| Merlini, G | 1 |
| Spencer, A | 1 |
| Leleu, X | 1 |
| Cavo, M | 1 |
| Munshi, N | 1 |
| Rajkumar, SV | 1 |
| Durie, BG | 1 |
| Roodman, GD | 1 |
| Alegre, A | 1 |
| Gironella, M | 1 |
| Bailén, A | 1 |
| Giraldo, P | 1 |
| Papamerkouriou, YM | 1 |
| Kenanidis, E | 1 |
| Gamie, Z | 1 |
| Papavasiliou, K | 1 |
| Kostakos, T | 1 |
| Potoupnis, M | 1 |
| Sarris, I | 1 |
| Tsiridis, E | 1 |
| Kyrkos, J | 1 |
| Criscitiello, C | 1 |
| Viale, G | 1 |
| Gelao, L | 1 |
| Esposito, A | 1 |
| De Laurentiis, M | 1 |
| De Placido, S | 1 |
| Santangelo, M | 1 |
| Goldhirsch, A | 1 |
| Curigliano, G | 1 |
| Wang, Z | 1 |
| Qiao, D | 1 |
| Lu, Y | 1 |
| Curtis, D | 1 |
| Wen, X | 1 |
| Yao, Y | 1 |
| Zhao, H | 1 |
| Berenson, J | 1 |
| Cook, RJ | 1 |
| Lipton, A | 4 |
| Coleman, RE | 3 |
| Spence, MM | 1 |
| Hui, RL | 1 |
| Chan, J | 1 |
| Schottinger, JE | 1 |
| Gimsing, P | 2 |
| Carlson, K | 1 |
| Fayers, P | 1 |
| Waage, A | 1 |
| Vangsted, A | 1 |
| Mylin, A | 1 |
| Gluud, C | 1 |
| Juliusson, G | 1 |
| Gregersen, H | 1 |
| Hjorth-Hansen, H | 1 |
| Nesthus, I | 1 |
| Dahl, IM | 1 |
| Westin, J | 2 |
| Nielsen, JL | 1 |
| Knudsen, LM | 1 |
| Ahlberg, L | 1 |
| Hjorth, M | 1 |
| Abildgaard, N | 2 |
| Andersen, NF | 1 |
| Linder, O | 1 |
| Wisløff, F | 1 |
| D'Arena, G | 1 |
| Gobbi, PG | 1 |
| Broglia, C | 1 |
| Sacchi, S | 1 |
| Quarta, G | 1 |
| Baldini, L | 1 |
| Iannitto, E | 1 |
| Falcone, A | 1 |
| Guariglia, R | 1 |
| Pietrantuono, G | 1 |
| Villani, O | 1 |
| Martorelli, MC | 1 |
| Mansueto, G | 1 |
| Sanpaolo, G | 1 |
| Cascavilla, N | 1 |
| Musto, P | 1 |
| Pozzi, S | 1 |
| Ludwig, H | 1 |
| Zojer, N | 1 |
| Redzepovic, J | 1 |
| Wheatley, K | 1 |
| Clark, OA | 1 |
| Glasmacher, A | 1 |
| Murphy, L | 1 |
| McCarthy, J | 1 |
| McCrate, F | 1 |
| Laing, K | 1 |
| Powell, E | 1 |
| Seal, M | 1 |
| Edwards, S | 1 |
| Cloos, PA | 1 |
| Fledelius, C | 1 |
| Christgau, S | 1 |
| Christiansen, C | 1 |
| Engsig, M | 1 |
| Delmas, P | 1 |
| Body, JJ | 1 |
| Garnero, P | 1 |
| Leng, Y | 1 |
| Chen, SL | 1 |
| Shi, HZ | 1 |
| Robinson, C | 1 |
| Baker, N | 1 |
| Noble, J | 1 |
| King, A | 1 |
| David, G | 1 |
| Sillence, D | 1 |
| Hofman, P | 1 |
| Cundy, T | 1 |
| Fan, SL | 1 |
| Kumar, S | 1 |
| Cunningham, J | 1 |
| Rosen, LS | 1 |
| Gordon, D | 1 |
| Kaminski, M | 1 |
| Howell, A | 1 |
| Belch, A | 1 |
| Mackey, J | 1 |
| Apffelstaedt, J | 1 |
| Hussein, MA | 1 |
| Reitsma, DJ | 2 |
| Chen, BL | 1 |
| Seaman, JJ | 2 |
| Gordon, CM | 1 |
| Bachrach, LK | 1 |
| Carpenter, TO | 1 |
| Karsenty, G | 1 |
| Rauch, F | 1 |
| Lee, S | 1 |
| Glicklich, D | 1 |
| Coco, M | 1 |
| Ward, K | 1 |
| Cowell, CT | 1 |
| Little, DG | 1 |
| Liauw, W | 1 |
| Segelov, E | 1 |
| Lih, A | 1 |
| Dunleavy, R | 1 |
| Links, M | 1 |
| Ward, R | 1 |
| Attal, M | 1 |
| Harousseau, JL | 1 |
| Leyvraz, S | 1 |
| Doyen, C | 1 |
| Hulin, C | 1 |
| Benboubker, L | 1 |
| Yakoub Agha, I | 1 |
| Bourhis, JH | 1 |
| Garderet, L | 1 |
| Pegourie, B | 1 |
| Dumontet, C | 1 |
| Renaud, M | 1 |
| Voillat, L | 1 |
| Berthou, C | 1 |
| Marit, G | 1 |
| Monconduit, M | 1 |
| Caillot, D | 1 |
| Grobois, B | 1 |
| Avet-Loiseau, H | 1 |
| Moreau, P | 1 |
| Facon, T | 1 |
| Clemons, M | 1 |
| Dranitsaris, G | 1 |
| Ooi, W | 1 |
| Cole, DE | 1 |
| Mautalen, CA | 1 |
| Casco, CA | 1 |
| Gonzalez, D | 1 |
| Ghiringhelli, GR | 1 |
| Massironi, C | 1 |
| Fromm, GA | 1 |
| Plantalech, L | 1 |
| Samuel, R | 1 |
| Katz, K | 1 |
| Papapoulos, SE | 1 |
| Yosipovitch, Z | 1 |
| Zaizov, R | 1 |
| Liberman, UA | 1 |
| Bembi, B | 1 |
| Agosti, E | 1 |
| Boehm, P | 1 |
| Nassimbeni, G | 1 |
| Zanatta, M | 1 |
| Vidoni, L | 1 |
| Diamond, T | 1 |
| Depczynski, B | 1 |
| Thiébaud, D | 1 |
| Sauty, A | 1 |
| Burckhardt, P | 1 |
| Leuenberger, P | 1 |
| Sitzler, L | 1 |
| Green, JR | 1 |
| Kandra, A | 2 |
| Zieschang, J | 1 |
| Ibarra de Palacios, P | 1 |
| Berenson, JR | 1 |
| Purohit, OP | 1 |
| Vinholes, JJ | 1 |
| Zekri, J | 1 |
| Brincker, H | 1 |
| Hedenus, M | 1 |
| Ford, J | 1 |
| Rosano, TG | 1 |
| Peaston, RT | 1 |
| Bone, HG | 1 |
| Woitge, HW | 1 |
| Francis, RM | 1 |
| Seibel, MJ | 2 |
| Broyles, DL | 1 |
| Nielsen, RG | 1 |
| Bussett, EM | 1 |
| Lu, WD | 1 |
| Mizrahi, IA | 1 |
| Nunnelly, PA | 1 |
| Ngo, TA | 1 |
| Noell, J | 1 |
| Christenson, RH | 1 |
| Kress, BC | 1 |
| Haworth, CS | 2 |
| Selby, PL | 2 |
| Webb, AK | 2 |
| Mawer, EB | 1 |
| Adams, JE | 2 |
| Freemont, TJ | 2 |
| Theriault, RL | 1 |
| Hortobagyi, GN | 1 |
| Leff, R | 1 |
| Glück, S | 1 |
| Stewart, JF | 1 |
| Costello, S | 1 |
| Kennedy, I | 1 |
| Simeone, J | 1 |
| Knight, RD | 1 |
| Mellars, K | 1 |
| Heffernan, M | 1 |
| Teramoto, S | 1 |
| Matsuse, T | 1 |
| Ouchi, Y | 1 |
| Thürlmann, B | 1 |
| Cohen, H | 1 |
| Alferiev, IS | 1 |
| Mönkkönen, J | 1 |
| Pinto, T | 1 |
| Ezra, A | 1 |
| Solomon, V | 1 |
| Stepensky, D | 1 |
| Sagi, H | 1 |
| Ornoy, A | 1 |
| Patlas, N | 1 |
| Hägele, G | 1 |
| Hoffman, A | 1 |
| Breuer, E | 1 |
| Golomb, G | 1 |
| Lortholary, A | 1 |
| Jadaud, E | 1 |
| Berthaud, P | 1 |
| Vega, D | 1 |
| Fernández, D | 1 |
| Ellena, JA | 1 |
| Armingaud, P | 1 |
| Zerkak, D | 1 |
| Lespessailles, E | 1 |
| Petavy-Catala, C | 1 |
| Kerdraon, R | 1 |
| Benhamou, CL | 1 |
| Estève, E | 1 |
| Ostlere, L | 1 |
| Warner, T | 1 |
| Meunier, PJ | 1 |
| Hulme, P | 1 |
| Hesp, R | 1 |
| Watts, RW | 1 |
| Reeve, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer: A Non-inferiority, Randomized, Open, Parallel and Controlled Prospective Clinical Study[NCT02480634] | Phase 4 | 280 participants (Anticipated) | Interventional | 2019-06-30 | Not yet recruiting | ||
| The Effect of i.v. Bisphosphonate on Health-Related Quality of Life and Skeletal Morbidity for Newly Diagnosed Treatment Demanding Multiple Myeloma. A Prospective Randomised Double Blinded Dose-Effective Study With Cost-Utility Analysis.[NCT00376883] | Phase 3 | 500 participants | Interventional | 2000-01-31 | Completed | ||
| An International, Multicenter, Non-Randomized, Open-Labeled Study to Evaluate the Efficacy of Lower Dose Dexamethasone/Thalidomide and Higher Frequency ZOMETA(TM) in the Treatment of Previously Untreated Patients With Multiple Myeloma[NCT00263484] | Phase 2 | 56 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420] | Phase 1 | 4 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Early Initiated Individualized Physical Training in Newly Diagnosed Multiple Myeloma Patients; Effects on Physical Function, Physical Activity, Quality of Life, Pain, and Bone Disease.[NCT02439112] | 102 participants (Actual) | Interventional | 2015-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
16 reviews available for pamidronate and Bone Diseases
| Article | Year |
|---|---|
Bisphosphonates, Old Friends of Bones and New Trends in Clinics.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Drug Compo | 2021 |
Multidisciplinary Multiagent Treatment of Complex Lymphatic Anomalies with Severe Bone Disease: A Single-Site Experience.
Topics: Bone Diseases; Female; Humans; Lymphatic Abnormalities; Pamidronate; Sirolimus; Vincristine | 2022 |
Bisphosphonates in multiple myeloma: an updated network meta-analysis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Diphosphonat | 2017 |
Zoledronic acid in the management of bone disease as a consequence of multiple myeloma: a review.
Topics: Antineoplastic Agents; Bone Diseases; Clodronic Acid; Diphosphonates; Drug Monitoring; Humans; Iband | 2014 |
Treatment of multiple myeloma bone disease: experimental and clinical data.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Diseases; Bone Neoplasms; De | 2015 |
Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone and Bones; Bone Density Cons | 2015 |
Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis.
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Denosumab; Diphosphonates; Humans; | 2015 |
The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.
Topics: Acute-Phase Reaction; Bone Diseases; Diphosphonates; Endothelial Cells; Humans; Imidazoles; Multiple | 2011 |
Supportive therapy in multiple myeloma.
Topics: Anemia; Blood Transfusion; Bone Diseases; Calcitonin; Clodronic Acid; Diphosphonates; Erythropoietin | 2011 |
Bisphosphonates in multiple myeloma: a network meta-analysis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Diphosphonat | 2012 |
Bone health in children and adolescents: a symposium at the annual meeting of the Pediatric Academic Societies/Lawson Wilkins Pediatric Endocrine Society, May 2003.
Topics: Adolescent; Adrenergic beta-Antagonists; Animals; Bone and Bones; Bone Density; Bone Diseases; Child | 2004 |
New therapeutic agents for the treatment of bone diseases.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Bone Diseases, Metabolic; Bo | 2005 |
Bisphosphonates and breast carcinoma.
Topics: Bone Diseases; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcification, Physiologic; Clinic | 1997 |
Bisphosphonates in multiple myeloma.
Topics: Bone Diseases; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Multiple Mye | 1997 |
Bisphosphonates in clinical oncology. The development of pamidronate.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone and Bones; Bone Diseases; Bone Neoplasms | 1999 |
[Bisphosphonates and bone metastases].
Topics: Antineoplastic Agents; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonat | 1999 |
16 trials available for pamidronate and Bone Diseases
| Article | Year |
|---|---|
Risk of skeletal-related events in patients with advanced prostate cancer treated with pamidronate or zoledronic acid.
Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Humans | 2010 |
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation A | 2010 |
Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Dis | 2011 |
[Effects of pamidronate disodium (Bonin) combined with chemotherapy on bone pain in multiple myeloma].
Topics: Adult; Aged; Antineoplastic Agents; Bone Diseases; Clinical Trials as Topic; Diphosphonates; Drug Th | 2002 |
Long-term effects on bone mineral density of pamidronate given at the time of renal transplantation.
Topics: Adult; Aged; Anti-Inflammatory Agents; Bone Density; Bone Diseases; Diphosphonates; Femur Neck; Foll | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Pamidronate used to attenuate post-renal transplant bone loss is not associated with renal dysfunction.
Topics: Anti-Inflammatory Agents; Bone Density; Bone Diseases; Creatinine; Diphosphonates; Humans; Infusions | 2004 |
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Diseases; Diphosphonates; Disease-Free Su | 2006 |
A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density Conservation Agen | 2008 |
An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates.
Topics: Acute-Phase Reaction; Adult; Bone Diseases; Carrier Proteins; Clodronic Acid; Diphosphonates; Female | 1997 |
Bisphosphonates in multiple myeloma.
Topics: Bone Diseases; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Multiple Mye | 1997 |
High dose pamidronate: clinical and biochemical effects in metastatic bone disease.
Topics: Biomarkers, Tumor; Bone Diseases; Breast Neoplasms; Collagen; Diphosphonates; Female; Humans; Male; | 1997 |
Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols | 1998 |
Urinary free deoxypyridinoline by chemiluminescence immunoassay: analytical and clinical evaluation.
Topics: Adult; Amino Acids; Animals; Antibodies, Monoclonal; Biomarkers; Bone Diseases; Diphosphonates; Fema | 1998 |
Severe bone pain after intravenous pamidronate in adult patients with cystic fibrosis.
Topics: Adult; Anti-Inflammatory Agents; Bone Density; Bone Diseases; Cystic Fibrosis; Diphosphonates; Dose- | 1998 |
Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Disea | 1999 |
23 other studies available for pamidronate and Bone Diseases
| Article | Year |
|---|---|
Use of Bisphosphonates in Elderly Patients With Newly Diagnosed Multiple Myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation A | 2019 |
In silico investigations of potential anabolic treatments in multiple myeloma-induced bone disease.
Topics: Anabolic Agents; Bone Diseases; Boronic Acids; Bortezomib; Calibration; Cell Count; Computer Simulat | 2013 |
International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.
Topics: Administration, Intravenous; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Combin | 2013 |
Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Bone Diseases; Clinica | 2010 |
Intravenous pamidronate for myeloma bone disease: can the dose be lowered?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Diseases; Cli | 2010 |
In silico investigations of the anti-catabolic effects of pamidronate and denosumab on multiple myeloma-induced bone disease.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone and Bones; Bone Diseases; Calibration | 2012 |
Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Bre | 2013 |
Investigation of bone disease using isomerized and racemized fragments of type I collagen.
Topics: Adult; Aged; Biomarkers; Bone Diseases; Bone Neoplasms; Bone Resorption; Cells, Cultured; Collagen; | 2003 |
The osteodystrophy of mucolipidosis type III and the effects of intravenous pamidronate treatment.
Topics: Absorptiometry, Photon; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Bone Density; Bone Dise | 2002 |
Quantification of metaphyseal modeling in children treated with bisphosphonates.
Topics: Adolescent; Bone Development; Bone Diseases; Child; Child, Preschool; Diphosphonates; Female; Femur; | 2005 |
Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer.
Topics: Aged; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Dis | 2005 |
Side effects of disodium aminohydroxypropylidenediphosphonate (APD) during treatment of bone diseases.
Topics: Bone Diseases; Diphosphonates; Humans; Pamidronate | 1984 |
Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher's disease.
Topics: Adolescent; Bone Diseases; Diphosphonates; Female; Femur; Follow-Up Studies; Fractures, Spontaneous; | 1994 |
Aminohydroxypropylidene-biphosphonate in the treatment of bone lesions in a case of Gaucher's disease type 3.
Topics: Bone Diseases; Child, Preschool; Diphosphonates; Female; Gaucher Disease; Humans; Pamidronate | 1994 |
Pamidronate disodium reduces skeletal complications of multiple myeloma.
Topics: Bone Diseases; Diphosphonates; Fractures, Spontaneous; Humans; Multiple Myeloma; Osteolysis; Pamidro | 1996 |
Acquired osteosclerosis associated with intravenous drug use and hepatitis C infection.
Topics: Adult; Bone Density; Bone Diseases; Diphosphonates; Femur; Hepatitis C; Humans; Lumbar Vertebrae; Ma | 1996 |
Analytical and clinical performance characteristics of Tandem-MP Ostase, a new immunoassay for serum bone alkaline phosphatase.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone and Bones; Bone Diseases; Bon | 1998 |
Increased cytokines and pamidronate-induced bone pain in adults with cystic fibrosis.
Topics: Adult; Anti-Inflammatory Agents; Bone Diseases; Cystic Fibrosis; Diphosphonates; Humans; Pain; Pamid | 1999 |
Oral corticosteroids and bone pain after pamidronate in adults with cystic fibrosis.
Topics: Adult; Anti-Infective Agents; Bone Diseases; Cystic Fibrosis; Diphosphonates; Glucocorticoids; Human | 1999 |
Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio) ethylidene-1,1-bisphosphonic acid betaine (ISA-13-1)-a novel bisphosphonate.
Topics: Administration, Oral; Alendronate; Animals; Antineoplastic Agents; Betaine; Bone Diseases; Bone Neop | 1999 |
Disodium pamidronate.
Topics: Bone Diseases; Crystallography, X-Ray; Diphosphonates; Hydrogen Bonding; Models, Molecular; Pamidron | 2002 |
[Bone evaluation in ten adults with cutaneous mastocytosis].
Topics: Adult; Anti-Inflammatory Agents; Bone Density; Bone Diseases; Bone Diseases, Metabolic; Bone Marrow | 2002 |
Treatment of type 1 Gaucher's disease affecting bone with aminohydroxypropylidene bisphosphonate (pamidronate).
Topics: Adult; Bone and Bones; Bone Density; Bone Diseases; Bone Marrow; Calcium; Diphosphonates; Female; Ga | 1991 |